RxDoctor Payments Data

Humberto Caldera, MD

Hematology & Oncology · Lake Worth, FLNPI 1891749164

Payments from drug & device makers

$67,076in general payments, 2019–2025

Across 1,334 payments — averaging $50.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$16K
  • AstraZeneca$10K
  • Incyte Corporation$5K
  • Pfizer$4K
  • Johnson & Johnson$4K
  • Beigene USA, Inc.$4K
  • plus $25K from 54 others

What the payments were for

  • Consulting fees$17,52526%
  • Speaking & faculty fees$17,14026%
  • Travel & lodging$3,5635%
  • Food & beverage$27,66941%
  • Education$1,1792%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.33$15,691
AstraZeneca(2 entities)109$9,985
Incyte Corporation36$4,717
Pfizer122$3,609
Johnson & Johnson(3 entities)99$3,527
Beigene USA, Inc.16$3,517
Seagen Inc.33$2,107
Pharmacosmos Therapeutics Inc.8$1,799
Puma Biotechnology, Inc.36$1,638
Bayer23$1,582
E.r. Squibb & Sons, L.L.C.87$1,429
Merck64$1,294
Sanofi42$1,149
Bristol Myers Squibb65$1,117
Sirtex Medical Inc11$952
Novartis53$943
Amgen31$809
Astellas Pharma US Inc26$746
Genentech USA, Inc.36$739
Daiichi Sankyo Inc.37$726
Lilly USA, LLC34$604
Tempus AI, Inc14$553
EMD Serono, Inc.24$481
AbbVie23$477
Exelixis Inc.24$477
Pharmacyclics LLC, An Abbvie Company16$414
Boehringer Ingelheim10$409
Stemline Therapeutics Inc.5$396
GSK21$379
Regeneron Healthcare Solutions, Inc.10$378
Jazz Pharmaceuticals Inc.19$348
Eisai Inc.14$341
Novocure Inc.2$277
Gilead(2 entities)11$222
Array Biopharma Inc12$207
Ipsen Biopharmaceuticals, Inc9$200
AVEO Pharmaceuticals, Inc.4$200
G1 Therapeutics, Inc.2$136
Adaptive Biotechnologies Corporation6$136
Advanced Accelerator Applications2$125
Karyopharm Therapeutics Inc.7$101
Mirati Therapeutics, Inc.4$94
Avyxa Pharma, LLC1$91
Servier Pharmaceuticals LLC4$90
Kyowa Kirin, Inc.5$88
Sobi, Inc4$88
Rigel Pharmaceuticals, Inc.3$87
Alnylam Pharmaceuticals Inc.4$82
Geron Corporation4$82
Deciphera Pharmaceuticals Inc.4$82
Tersera Therapeutics LLC3$77
Medtronic1$77
ADC Therapeutics America, Inc.4$74
Caris MPI, Inc.2$73
Taiho Oncology, Inc.4$73
Legend Biotech USA Inc.3$70
Dova Pharmaceuticals4$66
Blueprint Medicines Corporation3$60
Verastem, Inc.3$58
Recordati_rare_diseases_inc.3$54

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,076 in reported general payments places this provider in the 60th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$3,185,152
Medicare patients
433
Services billed
140,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide74$1,044,815
PomalystPomalidomide24$542,960
TagrissoOsimertinib Mesylate30$508,745
RevlimidLenalidomide35$504,212
VitrakviLarotrectinib Sulfate13$502,934
IbrancePalbociclib29$472,185
FruzaqlaFruquintinib19$466,961
CabometyxCabozantinib S-Malate17$417,316
TabrectaCapmatinib Hydrochloride13$280,895
XtandiEnzalutamide19$269,506
BrukinsaZanubrutinib15$216,823
MekinistTrametinib Dimethyl Sulfoxide14$215,708
TafinlarDabrafenib Mesylate14$199,166
VerzenioAbemaciclib13$197,671
ImbruvicaIbrutinib12$196,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$9,985$704,53543 claims
NovartisTabrecta, Mekinist, Tafinlar$943$695,76941 claims
PfizerIbrance, Eliquis$3,609$568,039184 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$1,429$542,96024 claims
Bristol Myers SquibbRevlimid$1,117$504,21235 claims
BayerVitrakvi$1,582$502,93413 claims
Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla$15,691$466,96119 claims
Exelixis Inc.Cabometyx$477$417,31617 claims
Astellas Pharma US IncXtandi$746$269,50619 claims
Beigene USA, Inc.Brukinsa$3,517$216,82315 claims
Lilly USA, LLCVerzenio$604$197,67113 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$414$196,05312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Lake Worth

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →